← Back to Clinical Trials
Recruiting NCT03449706

NCT03449706 Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03449706
Status Recruiting
Phase
Sponsor University Hospital, Ghent
Condition HIV
Study Type OBSERVATIONAL
Enrollment 70 participants
Start Date 2017-09-01
Primary Completion 2028-01-01

Trial Parameters

Condition HIV
Sponsor University Hospital, Ghent
Study Type OBSERVATIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2017-09-01
Completion 2028-01-01
Interventions
Early combination anti-retroviral treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cART) during acute seroconversion. Recently infected patients will be selected based on Fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. Immunological, virological and genome expression analysis will be performed on the gathered samples.

Eligibility Criteria

Inclusion Criteria: * Documented recent HIV-1 infection, early diagnosis: clinical symptoms of acute seroconversion and incomplete Western Blot OR negative screening test within the past 6 months and incomplete Western Blot OR risk contact within the 3 months and presumable primo-infection with or without clinical symptoms and incomplete Western Blot * Able and willing to provide written informed consent * Ability to attend the complete schedule of assessments and patient visits for patients participating in option A schedule (described below), or ability to attend a partial schedule of assessments and patient visits for patients participating in option B (described below). * Ability and willingness to have blood and tissue samples collected and stored indefinitely and used for various research purposes. Exclusion Criteria: * Previous or current history of opportunistic infection (AIDS defining events as defined in category C of the CDC clinical classification), consisting of chronic H

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology